SG10201407881WA - An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase - Google Patents

An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase

Info

Publication number
SG10201407881WA
SG10201407881WA SG10201407881WA SG10201407881WA SG10201407881WA SG 10201407881W A SG10201407881W A SG 10201407881WA SG 10201407881W A SG10201407881W A SG 10201407881WA SG 10201407881W A SG10201407881W A SG 10201407881WA SG 10201407881W A SG10201407881W A SG 10201407881WA
Authority
SG
Singapore
Prior art keywords
hemitartrate
glucosylceramide synthase
formula
genz
amorphous
Prior art date
Application number
SG10201407881WA
Other languages
English (en)
Inventor
Hanlan Liu
Chris Willis
Renu Bhardwaj
Diane P Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Jianmei Kochling
Gerard Palace
Judith Peterschmitt
Craig Siegel
Seng Cheng
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201407881W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG10201407881WA publication Critical patent/SG10201407881WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
SG10201407881WA 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase SG10201407881WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27

Publications (1)

Publication Number Publication Date
SG10201407881WA true SG10201407881WA (en) 2015-01-29

Family

ID=43431870

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201407881WA SG10201407881WA (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
SG10201800136QA SG10201800136QA (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201800136QA SG10201800136QA (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase

Country Status (41)

Country Link
US (6) US11458119B2 (fr)
EP (5) EP2504332B2 (fr)
JP (6) JP2013512252A (fr)
KR (5) KR20120115972A (fr)
CN (5) CN112521366A (fr)
AR (3) AR079152A1 (fr)
AU (3) AU2010324810B2 (fr)
BR (1) BR112012012947B8 (fr)
CA (3) CA2781676C (fr)
CL (2) CL2012001348A1 (fr)
CR (1) CR20120277A (fr)
CY (3) CY1115880T1 (fr)
DK (3) DK3133070T3 (fr)
DO (2) DOP2012000141A (fr)
EA (3) EA023923B1 (fr)
EC (2) ECSP12011926A (fr)
ES (4) ES2493940T5 (fr)
GT (1) GT201200161A (fr)
HK (2) HK1172031A1 (fr)
HR (3) HRP20140780T4 (fr)
HU (2) HUE029371T2 (fr)
IL (4) IL310635A (fr)
LT (2) LT3133070T (fr)
MA (1) MA33838B1 (fr)
ME (1) ME02477B (fr)
MX (1) MX358345B (fr)
MY (2) MY192644A (fr)
NI (1) NI201200096A (fr)
NZ (3) NZ715108A (fr)
PE (2) PE20121337A1 (fr)
PH (1) PH12015502514A1 (fr)
PL (4) PL2504332T5 (fr)
PT (4) PT3133070T (fr)
RS (3) RS59543B1 (fr)
SG (2) SG10201407881WA (fr)
SI (3) SI2504332T2 (fr)
SM (1) SMT201600273B (fr)
TN (1) TN2012000237A1 (fr)
TW (3) TWI656873B (fr)
UA (1) UA113491C2 (fr)
WO (1) WO2011066352A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (fr) 2004-07-01 2006-01-19 University Of Pennsylvania Remplacement de proteines ciblees pour le traitement de maladies lysosomales
CA2781676C (fr) 2009-11-27 2020-05-05 Genzyme Corporation Forme amorphe et cristalline de l'hemitartrate de genz 112638 au titre d'inhibiteur de la glucosylceramide synthetase
CN103764824B (zh) * 2011-06-20 2018-04-24 西奈山医学院 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法
EP3741384A1 (fr) 2011-09-07 2020-11-25 Mount Sinai School Of Medicine Céramidase et différenciation cellulaire
WO2013078413A1 (fr) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulateurs du stockage lipidique
CN104582770B (zh) 2012-06-01 2019-01-29 西奈山伊坎医学院 在感染的治疗和预防中的神经酰胺水平
PT2968479T (pt) 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização
AU2014321397C1 (en) * 2013-09-20 2019-08-01 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
WO2016001885A2 (fr) * 2014-07-03 2016-01-07 Dr. Reddy’S Laboratories Limited Forme amorphe d'hémitartrate d'eliglustat
ES2716420T3 (es) 2015-04-14 2019-06-12 Sandoz Ag Clorhidrato de eliglustat cristalino
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP6895963B2 (ja) 2015-11-18 2021-06-30 ジェンザイム・コーポレーション 多発性嚢胞腎のバイオマーカーおよびその使用
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (fr) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibiteurs de la synthase de glucosylcéramide pour le traitement de maladies du motoneurone
WO2018193090A2 (fr) * 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci
WO2018225085A1 (fr) 2017-06-05 2018-12-13 Cipla Limited Dispersions solides stables d'hémitartrate d'éliglustat
CN110799191B (zh) * 2017-06-16 2023-05-26 贝塔制药有限公司 N-(2-(2-(二甲氨基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)氨基)苯基)丙烯酰胺及其盐的药物制剂
US20200222310A1 (en) * 2017-08-08 2020-07-16 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
EP3664798A4 (fr) * 2017-08-08 2021-05-05 Kashiv Biosciences, LLC Composition pharmaceutique comprenant de l'éliglustat
MX2020006272A (es) 2017-12-15 2020-09-14 Genzyme Corp Metodos para tratar la enfermedad de gaucher.
WO2019123476A1 (fr) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Prémélange d'éliglustat amorphe stable et son procédé de préparation
WO2019211778A2 (fr) * 2018-05-02 2019-11-07 Kashiv Biosciences, Llc Pro-médicaments d'eliglustat
CN112512558A (zh) * 2018-05-27 2021-03-16 比奥阿赛斯技术有限公司 戈谢病的治疗
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
AU676361B2 (en) 1993-08-13 1997-03-06 Seikagaku Corporation Remedy for nervous diseases
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
PT742789E (pt) 1994-02-02 2000-12-29 Liposome Co Inc Lipossomas e compostos farmaceuticamente activos e metodos para a sua utilizacao
DE69524592T2 (de) 1994-06-10 2002-07-18 Seikagaku Kogyo Co Ltd 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
WO2001004108A1 (fr) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Composes de type amino-ceramide et procedes therapeutiques d'utilisation
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (fr) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Composes de type amino ceramide et leurs methodes d'utilisation therapeutiques
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6511979B1 (en) 1998-07-27 2003-01-28 Johns Hopkins University Methods for treating conditions modulated by lactosylceramide
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
CA2378600A1 (fr) * 1999-07-09 2001-01-18 The Regents Of The University Of Michigan Composes de type amino-ceramide et procedes therapeutiques d'utilisation
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
PT1473036E (pt) 2000-04-24 2006-10-31 Teva Pharma Solvato de hemitartarato de zolpidem
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
JP2004531478A (ja) 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
EP1392826A2 (fr) * 2001-01-18 2004-03-03 MERCK PATENT GmbH Proteines de fusion bifonctionnelles avec activite de la glucocerebrosidase
ES2399323T3 (es) 2001-07-16 2013-03-27 Genzyme Corporation Síntesis de inhibidores de la UDP-glucosa:N-acilesfingosina glucosiltransferasa
EP1281755A3 (fr) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants du gène humain cyp2d6
ES2376855T3 (es) 2001-08-08 2012-03-20 Tobira Therapeutics, Inc. Compuesto bicíclico, su preparación y su uso
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
WO2004004702A2 (fr) 2002-07-09 2004-01-15 The Scripps Research Institute Procede pour empecher les lesions par ischemie et reperfusion
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
DE602005027308D1 (de) * 2004-01-27 2011-05-19 Synthon Bv Stabile salze von olanzapin
EP1799865B1 (fr) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methodes d'administration d'iloperidone
EP1802589B1 (fr) 2004-10-13 2014-04-09 Pharmacia & Upjohn Company LLC Formes cristallines de 3-[5-chloro-4-(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
US8003617B2 (en) † 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
WO2007038676A2 (fr) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Formes polymorphiques de ladostigil tartrate
AU2006297475A1 (en) * 2005-10-03 2007-04-12 Mallinckrodt Inc. Process for preparing zolpidem hemitartrate and tartrate polymorphs
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
HUE026057T2 (en) * 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (fr) 2006-12-08 2008-08-27 Zealand Pharma A/S Peptides PTH tronqués à formation cyclique
AU2008232614A1 (en) * 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of Fabry disease using pharmacological chaperones
EP2150254A4 (fr) 2007-04-26 2010-11-10 Amicus Therapeutics Inc Schémas posologiques pour le traitement de maladies de stockage lysosomal en utilisant des chaperons pharmacologiques
WO2008150486A2 (fr) * 2007-05-31 2008-12-11 Genzyme Corporation Inhibiteurs de glucosylcéramide synthase de type 2-acylaminopropanol
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
US20090307179A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
WO2009117150A2 (fr) 2008-03-20 2009-09-24 Genzyme Corporation Méthode de traitement d’un lupus avec des dérivés de céramide
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
SI2604608T1 (sl) 2009-11-27 2015-12-31 Adverio Pharma Gmbh Postopek izdelave metil-(4,6-diamino-2(1-(2-fluorobenzil)-1H-pirazolo (3,4-b)piridin-3-il)-pirimidin-5-il)metil karbamata in njegovo čiščenje za uporabo kot farmacevtsko sredstvo
CA2781676C (fr) 2009-11-27 2020-05-05 Genzyme Corporation Forme amorphe et cristalline de l'hemitartrate de genz 112638 au titre d'inhibiteur de la glucosylceramide synthetase
RU2014101626A (ru) 2011-06-21 2015-07-27 Новартис Аг Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (fr) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Procédé de préparation d'hémitartrate d'eliglustat et d'intermédiaires de celui-ci

Also Published As

Publication number Publication date
EP3599237A1 (fr) 2020-01-29
CY1115880T1 (el) 2017-01-25
HRP20140780T4 (hr) 2021-08-06
ES2754398T3 (es) 2020-04-17
EA201592195A1 (ru) 2016-04-29
CN105753846B (zh) 2019-11-15
RS54978B1 (sr) 2016-11-30
CA3075788A1 (fr) 2011-06-03
TWI586663B (zh) 2017-06-11
CN112521367A (zh) 2021-03-19
CY1117996T1 (el) 2017-05-17
US10888547B2 (en) 2021-01-12
CA3140959A1 (fr) 2011-06-03
AR121612A2 (es) 2022-06-22
JP2016138124A (ja) 2016-08-04
EP2796457B1 (fr) 2016-05-18
IL283935A (en) 2021-07-29
EP3599237B1 (fr) 2021-03-24
TN2012000237A1 (en) 2013-12-12
TW201737910A (zh) 2017-11-01
CA2781676A1 (fr) 2011-06-03
US20130137743A1 (en) 2013-05-30
EP3133070B1 (fr) 2019-08-14
PT2504332E (pt) 2014-09-02
HK1203485A1 (zh) 2015-10-30
NI201200096A (es) 2012-10-30
SI3133070T1 (sl) 2019-11-29
JP2013512252A (ja) 2013-04-11
CN102712629A (zh) 2012-10-03
GT201200161A (es) 2014-01-27
EA201890254A3 (ru) 2019-02-28
HRP20161038T1 (hr) 2016-10-21
PT3599237T (pt) 2021-04-28
HUE045784T2 (hu) 2020-01-28
MY160542A (en) 2017-03-15
JP2019001809A (ja) 2019-01-10
PL2504332T3 (pl) 2014-10-31
TWI606827B (zh) 2017-12-01
US20210393590A1 (en) 2021-12-23
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
ECSP18063798A (es) 2020-02-28
DOP2012000141A (es) 2012-09-30
HK1172031A1 (en) 2013-04-12
AR079152A1 (es) 2011-12-28
HRP20140780T1 (en) 2014-11-07
AU2017265180B2 (en) 2019-08-01
US20210369672A1 (en) 2021-12-02
KR20200013105A (ko) 2020-02-05
US11458119B2 (en) 2022-10-04
PL2796457T3 (pl) 2017-04-28
BR112012012947B1 (pt) 2021-04-06
DOP2016000250A (es) 2017-02-15
NZ600155A (en) 2014-10-31
CL2016002589A1 (es) 2017-05-19
BR112012012947A2 (pt) 2017-03-01
NZ715108A (en) 2017-06-30
TW201130822A (en) 2011-09-16
TW201639562A (zh) 2016-11-16
JP2023116764A (ja) 2023-08-22
JP6452635B2 (ja) 2019-01-16
CN105777707B (zh) 2020-10-13
PT2796457T (pt) 2016-07-14
IL310635A (en) 2024-04-01
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
DK2504332T4 (da) 2021-06-07
WO2011066352A8 (fr) 2011-08-11
EP3133070A1 (fr) 2017-02-22
DK2504332T3 (da) 2014-08-25
RS53503B2 (sr) 2021-07-30
MX2012006083A (es) 2012-06-19
EP2504332B1 (fr) 2014-06-04
LT3133070T (lt) 2019-11-11
EA023923B1 (ru) 2016-07-29
PL2504332T5 (pl) 2021-08-23
TWI656873B (zh) 2019-04-21
CA3075788C (fr) 2021-12-21
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
DK2796457T3 (en) 2016-08-29
AU2017265180A1 (en) 2017-12-14
HUE029371T2 (en) 2017-02-28
SI2504332T1 (sl) 2014-09-30
EA029990B1 (ru) 2018-06-29
ES2493940T5 (es) 2021-11-23
LT2796457T (lt) 2016-09-12
BR112012012947B8 (pt) 2021-05-25
AU2016202591B2 (en) 2017-11-30
DK3133070T3 (da) 2019-11-11
US20160166542A1 (en) 2016-06-16
CA2781676C (fr) 2020-05-05
ES2586947T3 (es) 2016-10-19
MY192644A (en) 2022-08-29
EP3896069A1 (fr) 2021-10-20
EP2504332A1 (fr) 2012-10-03
CN102712629B (zh) 2016-10-12
US20230172903A1 (en) 2023-06-08
UA113491C2 (xx) 2017-02-10
CY1122698T1 (el) 2021-03-12
PL3133070T3 (pl) 2020-01-31
CN112521367B (zh) 2024-01-02
EA201270646A1 (ru) 2013-01-30
RS59543B1 (sr) 2019-12-31
EA201890254A2 (ru) 2018-10-31
PE20171255A1 (es) 2017-08-28
MA33838B1 (fr) 2012-12-03
EP2796457A1 (fr) 2014-10-29
IL260299A (en) 2018-08-30
KR20180049255A (ko) 2018-05-10
ES2493940T3 (es) 2014-09-12
KR20150125734A (ko) 2015-11-09
KR20120115972A (ko) 2012-10-19
SI2504332T2 (sl) 2021-08-31
EP2504332B2 (fr) 2021-03-17
RS53503B1 (en) 2015-02-27
JP7150528B2 (ja) 2022-10-11
PL3599237T3 (pl) 2021-09-27
AU2016202591A1 (en) 2016-05-19
CR20120277A (es) 2012-09-05
KR20220162824A (ko) 2022-12-08
US20160120842A1 (en) 2016-05-05
HRP20191647T1 (hr) 2019-12-13
AU2010324810A1 (en) 2012-06-07
ME02477B (fr) 2017-02-20
PH12015502514A1 (en) 2016-08-15
CL2012001348A1 (es) 2012-08-24
SI2796457T1 (sl) 2016-10-28
ES2875382T3 (es) 2021-11-10
PT3133070T (pt) 2019-11-11
JP2020189873A (ja) 2020-11-26
JP6370264B2 (ja) 2018-08-08
ECSP12011926A (es) 2012-07-31
SMT201600273B (it) 2016-08-31
IL219892A0 (en) 2012-07-31
JP2015212291A (ja) 2015-11-26
CN112521366A (zh) 2021-03-19
WO2011066352A1 (fr) 2011-06-03
SG10201800136QA (en) 2018-02-27
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14

Similar Documents

Publication Publication Date Title
PH12015502514A1 (en) An amorphous and crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
BR112013011991A2 (pt) composto, composição farmacêutica, uso de um composto, método de tratamento, produto, e kit.
WO2009066152A3 (fr) Inhibiteurs de ssao/vap-1 de type haloallylamines et leurs utilisations
BRPI0818893B8 (pt) compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula
MY160814A (en) Triazolopyridine compound,and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
BR112012011328A2 (pt) inibidores de akt
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
WO2012048129A3 (fr) Inhibiteurs de kinase de type polo
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
WO2009153178A3 (fr) Aryle cétone utilisé inhibiteur de la recapture des monoamines
WO2010091104A8 (fr) Inhibiteurs de la glucosylcéramide synthase
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX359069B (es) Sal y formas cristalinas de inhibidor de quinasa tipo polo-4.
WO2007098189A3 (fr) Nouvelle forme cristalline et compositions pharmaceutiques de (+)-r-zileuton
EA201270302A1 (ru) Безводные формы производных пиридина
MX355654B (es) Derivado de paroxetina.
TH135901B (th) ตัวยับยั้งกลูโคซิลเซอราไมด์ ซินเธส
TH135901A (th) ตัวยับยั้งกลูโคซิลเซอราไมด์ ซินเธส
EA201001239A1 (ru) Замещённые пиперидины в качестве ингибиторов ренина
TN2013000160A1 (en) Crystalline forms of hydrochloride salt of (4a-r,9a-s) -1- (1h - benzoimidazole- 5 -carbonyl) -2, 3, 4, 4a, 9, 9a - hexahydro -1h- indeno [2, 1 -b] pyridine- 6 -carbonitrile and their use as hsd 1 inhibitors